A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Syntrix Biosystems, Inc
This research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.
Enrollment Form
This study is currently enrolling.